Skip to main content
Article
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma
Journal of Immunotherapy (1996)
  • Robert G. Fenton, National Institutes of Health
  • Ronald G. Steis, National Institutes of Health
  • Karen Madara, Memorial Hospital of South Bend
  • Arnold H. Zea, Science Applications International Corporation
  • Augusto C. Ochoa, Science Applications International Corporation
  • John E. Janik, National Institutes of Health
  • John W. Smith, University of Michigan
  • Barry L. Gause, National Institutes of Health
  • William H. Sharfman, Johns Hopkins University
  • Walter J. Urba, Providence Portland Medical Center
  • Michael G. Hanna, University of Miami
  • Robert L. DeJager, University of Miami
  • Mark X. Coyne
  • Robert D. Crouch
  • Pat Gray, Memorial Hospital of South Bend
  • Joy Beveridge, National Institutes of Health
  • Stephen P. Creekmore, National Institutes of Health
  • Jon Holmlund, National Institutes of Health
  • Brendan D. Curti, National Institutes of Health
  • Mario Sznol, National Institutes of Health
  • Dan L. Longo, National Institutes of Health
Publication Date
January 9, 1996
DOI
10.1097/00002371-199609000-00006
Citation Information
Robert G. Fenton, Ronald G. Steis, Karen Madara, Arnold H. Zea, et al.. "A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma" Journal of Immunotherapy Vol. 19 Iss. 5 (1996) p. 364 - 374
Available at: http://works.bepress.com/walter-urba/246/